• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials
ConclusionIntravenous beta-blockers improved the MSI, decreased the risk of VT/VF in the first 24 h, and were associated with increased LVEF at 1 week and 6 months following PCI. In particular, intravenous beta-blockers started before PCI is beneficial for patients with LAD lesions.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research

Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology
Circulation. 2022 Apr 19;145(16):1254-1284. doi: 10.1161/CIRCULATIONAHA.121.058229. Epub 2022 Apr 18.ABSTRACTThe Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump that is currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of venoarterial extracorporeal membrane oxygenation and Impella concept), (3) high-risk percutaneous coronary interventions, (4) ablation of ventricular tachycardia, and (5) treatment of right ventricular failure. Impella-assisted forward blood flow increased mean arterial pressure and cardiac output, peripheral tissue pe...
Source: Circulation - April 18, 2022 Category: Cardiology Authors: Enzo L üsebrink Antonia Kellnar Kathrin Krieg Leonhard Binzenh öfer Clemens Scherer Sebastian Zimmer Benedikt Schrage Stephanie Fichtner Tobias Petzold Daniel Braun Sven Peterss Stefan Brunner Christian Hagl Dirk Westermann J örg Hausleiter Steffen Mas Source Type: research

Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction.
CONCLUSIONS: It is feasible to treat AMI patients with prasugrel. HTPR is a significant independent risk factor for adverse events in AMI patients receiving prasugrel after primary PCI. PMID: 27836373 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - November 7, 2016 Category: Cardiology Authors: Sato T, Namba Y, Kashihara Y, Tanaka M, Fuke S, Yumoto A, Saito H Tags: J Cardiol Source Type: research